Drug Profile


Alternative Names: AT-1001 - Alba Therapeutics; INN-202; Larazotide acetate; SPD 550

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Maryland School of Medicine
  • Developer Alba Therapeutics; Alba Therapeutics Corporation; Teva Pharmaceutical Industries
  • Class Oligopeptides
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Ulcerative colitis

Highest Development Phases

  • Phase II Coeliac disease
  • No development reported Crohn's disease; Irritable bowel syndrome
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Crohn's-disease in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Irritable-bowel-syndrome in USA (PO)
  • 06 Jun 2017 Innovate pharmaceuticals completes End-of-Phase II meeting with the US FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top